ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Celgene Will Acquire Drug Firm Gloucester

by Lisa M. Jarvis
December 14, 2009 | APPEARED IN VOLUME 87, ISSUE 50

Celgene has agreed to pay up to $640 million for Gloucester Pharmaceuticals, a Cambridge, Mass.-based firm that buys clinical-stage cancer drug candidates for further development. The deal expands Celgene’s blood-cancer drug portfolio, which already includes Revlimid for multiple myeloma and Vidaza for myelodysplastic syndromes. Last month, Gloucester’s histone deacetylase inhibitor, Istodax, won FDA approval for use in patients with cutaneous T-cell lymphoma. The companies expect to launch Istodax in early 2010. Glouce­ster’s owners get $340 million in cash and stand to receive an additional $300 million if regulatory milestones are met.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment